BioMarin’s Roctavian struggles continue. Is a divestment in the future?

Less than a year into a rocky rollout for its gene therapy Roctavian, BioMarin is now talking about whether the product might be a better fit outside the company, and cutting several pipeline programs.

On Wednesday, CEO Alexander Hardy said that the biotech company is looking at plans for the hemophilia A treatment, which brought in just $800,000 in the first quarter. If uptake doesn’t improve, Hardy said BioMarin may consider cutting the drug from its portfolio altogether.

Alexander Hardy

“Our focus is really on establishing the opportunity right now,” he said, noting during the company’s quarterly earnings call that BioMarin is not in active discussions for a sale of the product. “But should we remove it from the portfolio, we will absolutely look at the options around divesting.”

BioMarin also announced four early pipeline cuts, including two gene therapies,…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks